A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients.

Cancer Chemother Pharmacol · 2015 · PMC4365273 · PMID 25687989

Europe PMC DOI

hedged sentence

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

did not reach statistical significancep < 0.05actually significant

It was concluded that the observed trends between VEGF-2578C/A and K ss or VEGF-634G/C and K ss did not reach statistical significance as the required drop in OFV after the inclusion of VEGF-2578C/A or VEGF-634G/C was 6.8 points or 6.7 points, respectively ( p < 0.05, forward inclusion of one parameter).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.